Reuters : declared in Novartis wins speedy U.S. review of new leukemia drug

The medicine, called CTL019, is a treatment for young patients with B-cell acute lymphoblastic leukemia. FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File PhotoZURICH A new leukemia treatment from Novartis for children and young adults will get priority review from the U.S. Food and addiction Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. "With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options," Vas Narasimhan, Novartis head of drug development, said in a statement. Basel-based Novartis is now in pole position with regulators as it pushes for approval alongside rivals including biotech Kite Pharma Inc that are developing similar therapies.

Novartis wins speedy U.S. review of new leukemia drug

The medicine, called CTL019, is a treatment for young patients with B-cell acute lymphoblastic leukemia. FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File PhotoZURICH A new leukemia treatment from Novartis for children and young adults will get priority review from the U.S. Food and addiction Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. "With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options," Vas Narasimhan, Novartis head of drug development, said in a statement. Basel-based Novartis is now in pole position with regulators as it pushes for approval alongside rivals including biotech Kite Pharma Inc that are developing similar therapies.


The medicine, called CTL019, is a treatment for young patients with B-cell acute lymphoblastic leukaemia. [nL1N1DX1YD] "With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options," Vas Narasimhan, Novartis head of drug development, said in a statement. Novartis facebook/" target="_blank">shares were little changed on Thursday, but UK-based Oxford BioMedica , which makes ingredients for CTL019 and will reap undisclosed royalties from future sales, rose more than 4.5 percent on the announcement. In December, Novartis estimated 60 percent of those responders were relapse-free after six months. (Reporting by John Miller; Editing by Mark Potter) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)) Keywords: NOVARTIS CANCER/FILING (UPDATE 1)This article appears in: World Markets , Stocks , Economy , Commodities


collected by :Lucy William

To follow all the new news about Health care